Efficacy News and Research

RSS

Researchers develop diagnostic tool to examine traveling cancer cells, improve health outcomes

For most cancer patients, primary tumours are often not the most deadly. Instead, it is the metastatic tumours - tumours that spread from their original location to other parts of the body - that are the cause of most cancer deaths.

6 Nov 2014

Discovery Laboratories reports net loss of $11.3 million for third quarter 2014

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the third quarter ended September 30, 2014, as well as recent business updates.

6 Nov 2014

Acino recognized with 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership

Based on its recent analysis of the pharmaceutical drug delivery industry, Frost & Sullivan recognizes Acino Pharma AG with the 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership. Acino's expertise in targeted drug release profiles and strong technical know-how in pellet-coating, transdermal therapeutic patches and biodegradable implants has made it the preferred vendor in contract manufacturing.

6 Nov 2014

Janssen working with The Union to evaluate SIRTURO (bedaquiline) in patients with MDR-TB

Janssen Research & Development, LLC today announced a collaboration with the International Union Against Tuberculosis and Lung Disease (The Union) to include SIRTURO (bedaquiline) in the STREAM Study.

6 Nov 2014

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

5 Nov 2014

Cardio3 BioSciences announces acquisition of CorQuest Medical

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today that it has acquired U.S.-based CorQuest Medical Inc. CorQuest Medical specializes in the development of innovative devices and technologies for cardiac surgery.

5 Nov 2014

CARLINA, GenBiotech to jointly develop prolonged-release protein formulation for cartilage repair

CARLINA Technologies, a biotechnology company specialized in the development of nanomedicines, today announces the signing of a collaborative agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein. The resultant protein will be used in bone and cartilage repair. Financial details were not disclosed.

5 Nov 2014

Clinical study data of Advaxis' Lm-LLO immunotherapies to be presented at SITC Annual Meeting

Advaxis, Inc., a cancer immunotherapy company, today announced the abstracts of three preclinical and clinical studies highlighting the survival outcomes and anti-tumor effects of its proprietary Lm-LLO cancer immunotherapy technology at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting, November 6-9, 2014 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.

5 Nov 2014

Study suggests possible link between body fat and risk of immunotherapy toxicity

Immunotherapy that can be effective against tumors in young, thin mice can be lethal to obese ones, a new study by UC Davis researchers has found.

4 Nov 2014

Common drug could become the future standard of care for HE patients

A common drug used to clean a person's bowels before a colonoscopy could become the future standard of care for patients with acute hepatic encephalopathy (HE), a mental disorientation problem that affects up to one in two cirrhosis patients.

4 Nov 2014

Researchers identify genetic markers that play role in alcoholism recovery

In an international study, Mayo Clinic researchers and collaborators have identified genetic markers that may help in identifying individuals who could benefit from the alcoholism treatment drug acamprosate. The findings, published in the journal Translational Psychiatry, show that patients carrying these genetic variants have longer periods of abstinence during the first three months of acamprosate treatment.

4 Nov 2014

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca and Pharmacyclics, Inc. today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors.

4 Nov 2014

Ruthigen enrolls first patient in Phase 1/2 clinical trial of RUT58-60

Ruthigen, Inc., announced today enrollment of the first patient in a Randomized, Double-Blind Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of its lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery.

4 Nov 2014

Inventiva’s IVA337 receives EMA COMP positive opinion on orphan drug designation for SSc treatment

Inventiva, a drug discovery company that focuses on therapeutic approaches involving transcription factors and epigenetic targets, today announces that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has given a positive opinion on the designation of IVA337 as an orphan medicinal product.

4 Nov 2014

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

Merck Sharp & Dohme Ltd. MSD (known as Merck & Co., Inc. in the United States and Canada), today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection.

4 Nov 2014

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs.

4 Nov 2014

Transition Therapeutics presents Phase 2 study of ELND005 drug for bipolar disorder

Transition Therapeutics Inc. ("Transition" or the "Company") today announced findings from a Phase 2 study of neuropsychiatric drug candidate, ELND005, as an adjunctive maintenance treatment for bipolar disorder type I patients (BPD).

4 Nov 2014

UC Davis researchers link increased body fat and lethal drug reactions in mice

Immunotherapy that can be effective against tumors in young, thin mice can be lethal to obese ones, a new study by UC Davis researchers has found. The findings, published online today in The Journal of Experimental Medicine, suggest a possible link between body fat and the risk of toxicity from some types of immunotherapy.

3 Nov 2014

FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

Sanofi Pasteur, the vaccines division of Sanofi, today announced that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for Fluzone High-Dose (Influenza Vaccine) to include efficacy data in the Prescribing Information.

3 Nov 2014

Gates Foundation awards US$156 million to support PATH Malaria Vaccine Initiative

In support of a bold quest to rid the world entirely of malaria, the Bill & Melinda Gates Foundation today announced an award of US$156 million to PATH to support the PATH Malaria Vaccine Initiative (MVI) in building new vaccines that will interrupt the cycle of malaria parasite transmission and help realize the "accelerating to zero" agenda. Such vaccines would ensure that parasite reintroduction is prevented by providing what could be called an "immunological bed net."

3 Nov 2014

Efficacy News and Research

Researchers develop diagnostic tool to examine traveling cancer cells, improve health outcomes

Discovery Laboratories reports net loss of $11.3 million for third quarter 2014

Acino recognized with 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership

Janssen working with The Union to evaluate SIRTURO (bedaquiline) in patients with MDR-TB

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Cardio3 BioSciences announces acquisition of CorQuest Medical

CARLINA, GenBiotech to jointly develop prolonged-release protein formulation for cartilage repair

Clinical study data of Advaxis' Lm-LLO immunotherapies to be presented at SITC Annual Meeting

Study suggests possible link between body fat and risk of immunotherapy toxicity

Common drug could become the future standard of care for HE patients

Researchers identify genetic markers that play role in alcoholism recovery

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

Ruthigen enrolls first patient in Phase 1/2 clinical trial of RUT58-60

Inventiva’s IVA337 receives EMA COMP positive opinion on orphan drug designation for SSc treatment

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

Transition Therapeutics presents Phase 2 study of ELND005 drug for bipolar disorder

UC Davis researchers link increased body fat and lethal drug reactions in mice

FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

Gates Foundation awards US$156 million to support PATH Malaria Vaccine Initiative

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News